drugset / Trial / NCT07552376
This Study Aims to Evaluate the Efficacy and Safety of QLS1317 in Patients With MSI-H/dMMR Advanced Solid Tumors.
Phase 1
Not yet recruiting
120 enrolled
Shanghai Qilu Pharmaceutical Research and Development Center LTD
NaSingle-groupOpen-labelTreatment
Summary
The goal of this study aims to evaluate the efficacy and safety of QLS1317 in patients with MSI-H/dMMR advanced solid tumors who failed standard treatment.
Timeline
- Start
- 2026-05
- Primary completion
- 2028-06
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QLS1317 | Unknown | — | — |
Indications
No indication recorded.